Innovotech Inc.

Innovotech Inc.

October 31, 2013 06:00 ET

Innovotech Announces New Director and Grant of Stock Options

EDMONTON, ALBERTA--(Marketwired - Oct. 31, 2013) - Innovotech Inc. (TSX VENTURE:IOT) ("Innovotech") is pleased to announce the appointment of Robert Huizinga to its board of directors. Mr. Huizinga is currently Vice President, Clinical Affairs of Aurinia Pharmaceuticals Inc., formerly Isotechnika Pharma Inc. Prior to this, Mr. Huizinga was at the University of Alberta Hospitals in the Division of Nephrology & Immunology as a Nephrology Nurse Clinician and Research Epidemiologist. He holds a Master's Degree in Medical Sciences - Epidemiology, is a Registered Nurse and has published many articles with respect to his areas of expertise.

Dr. James Timourian, Chairman of the Board of Directors of Innovotech, states, "Mr. Huizinga has over twenty years of experience in clinical research. I look forward to the insights he will bring to the board of directors and believe his appointment will be a great asset to Innovotech."

As part of Mr. Huizinga's compensation for joining the board of directors, he will receive 30,000 stock options to purchase common shares of Innovotech at an exercise price of $0.085 per common share effective October 31, 2013 pursuant to Innovotech's stock option plan. The stock options expire October 30, 2023.

Mr. Huizinga replaces Dr. Lorne Babiuk who has tendered his resignation from the Board of Directors due to his many commitments as Vice President Research of the University of Alberta. Dr. Timourian added, "we sincerely thank Dr. Babiuk for his very valuable contributions of and consistent support for Innovotech, as well as for his offer to be available for consultation whenever needed."

About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are organized communities of microorganisms that exist in virtually every natural environment and are responsible for a host of diseases in human health, animal health and agriculture. There are few products or regulatory standards, aside from those of Innovotech, designed specifically for biofilm-forming organisms.

Innovotech has a broad range of products that address the issue of biofilms within a number of different industries, including commercially available products in a variety of market segments; the MBEC Assay™, InnovoSIL™, bioFILM PA™, InnovoSCEPT-Human and InnovoSCEPT-Veterinary kits. The MBEC Assay™ is a high throughput biofilm growth device that was recently approved as an ASTM International standard. InnovoSIL™ is a family of silver-based antimicrobials promising superior performance for medical device coatings, bioFILM PA™ and InnovoSCEPT-Human are the first diagnostic tests to assist physicians in the selection of the most effective antibiotic treatment for patients with biofilm-based chronic infections, while the InnovoSCEPT veterinary tests are designed to determine the most effective antibiotic treatment for infections for chronic infections in both large and small animals. Agress® and AgreGuard™ are unique, environmentally friendly seed treatments and plan sprays designed to protect crops against both bacterial and fungal infections. Agress® is entering the regulatory approval stage.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information